Daiichi Sankyo Europe, GmbH
Clinical trials sponsored by Daiichi Sankyo Europe, GmbH, explained in plain language.
European subsidiary of Daiichi Sankyo, a global pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Thousands tracked: does bempedoic acid work in real life? Results expected Oct 2026 (estimated)
- New drug under Real-World watch for tough stomach cancer Results expected Dec 2026 (estimated)
- New triple therapy shows promise for stubborn high cholesterol Results expected Jul 2027 (estimated)
-
New triple therapy shows promise for stubborn high cholesterol
Disease control Recruiting nowThis study looks at how well a combination of three cholesterol-lowering medicines (bempedoic acid, ezetimibe, and a statin) works in real-world patients with high cholesterol or mixed lipid problems. About 2,000 adults at high or very high risk will be followed for up to a year.…
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New study tracks how a targeted drug stacks up against chemo for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study follows over 1,100 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. Researchers will compare how long patients stay on trastuzumab deruxtecan (a targeted drug) versus standard chemotherapy before needing a new treatment. The goal is t…
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC